$93 Million is the total value of VHCP Management, LLC's 21 reported holdings in Q4 2016. The portfolio turnover from Q3 2016 to Q4 2016 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| RGNX | Exit | REGENXBIO Inc | $0 | – | -24,089 | -100.0% | -0.33% | – |
| ACHN | Exit | Achillion Pharmaceuticals Inc | $0 | – | -180,000 | -100.0% | -1.43% | – |
| BGNE | Exit | BeiGene Ltd | $0 | – | -51,000 | -100.0% | -1.54% | – |
| ZFGN | Exit | Zafgen Inc | $0 | – | -602,114 | -100.0% | -1.96% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-02-13
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| DBV Technologies | 14 | Q4 2016 | 33.5% |
| BioCryst Pharmaceuticals Inc | 13 | Q4 2016 | 11.9% |
| Ocera Therapeutics | 13 | Q4 2016 | 4.9% |
| Anacor Pharmaceuticals Inc | 12 | Q1 2016 | 35.6% |
| Heron Therapeutics Inc | 12 | Q4 2016 | 20.5% |
| Flamel Technologies S.A. | 12 | Q4 2016 | 6.1% |
| GW Pharmaceuticals | 11 | Q4 2015 | 19.9% |
| Lipocine Inc | 11 | Q4 2016 | 7.5% |
| Stemline Therapeutics Inc | 11 | Q4 2016 | 1.7% |
| Zafgen Inc | 10 | Q3 2016 | 5.7% |
View VHCP Management, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2018-02-28 |
| 13F-HR | 2017-02-13 |
| 13F-HR | 2016-11-14 |
| 13F-HR | 2016-08-12 |
| 13F-HR | 2016-05-13 |
| 13F-HR | 2016-02-12 |
| 13F-HR | 2015-11-13 |
| 13F-HR | 2015-08-13 |
| 3 | 2015-06-17 |
| 13F-HR | 2015-05-14 |
View VHCP Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.